STOCK TITAN

Evolus Stock Price, News & Analysis

EOLS NASDAQ

Company Description

Overview

Evolus Inc is a performance beauty company that specializes in innovative medical aesthetic products. Focused on the self-pay aesthetic market, the company brings breakthrough technologies to cosmetic medicine with a customer-centric approach. Its flagship product, Jeuveau, is a proprietary purified botulinum toxin type A formulation designed to temporarily improve the appearance of moderate to severe glabellar lines, a key concern in cosmetic procedures.

Business Model

Evolus operates primarily within the medical aesthetic landscape by targeting physicians and their patients. The company generates revenue through the direct sale of its groundbreaking Jeuveau formulation in major markets such as the United States and Europe, and it also benefits from service revenues sourced through distribution partnerships, including arrangements in Canada. This dual-channel approach underscores the company’s focus on both product innovation and efficient market distribution.

Product and Technology

The core of Evolus’ value proposition lies in its proprietary technology. Jeuveau, with its 900 kilodalton purified botulinum toxin type A formulation, stands as a testament to the company’s commitment to advanced formulations and clinical efficacy. This product is engineered for temporary aesthetic enhancements, addressing the cosmetic needs associated with visible facial lines and contributing to a refined treatment portfolio in non-invasive cosmetic procedures.

Market Position and Competitive Landscape

Evolus has established a niche in the competitive self-pay aesthetic market by focusing on high-quality performance beauty solutions. The company differentiates itself through its innovative product formulation, rigorous clinical standards, and a strong focus on customer outcomes. As such, it competes with a range of established as well as emerging players in the realm of aesthetic medicine, carving out a unique position by delivering specialized products that directly address aesthetic concerns in a controlled medical environment.

Operational Excellence and Industry Credentials

With deep expertise in the field of medical aesthetics, Evolus has continuously leveraged scientific rigor and customer insights to refine its product offerings. The company’s operations are designed to optimize product distribution and regulatory compliance while maintaining a focus on patient safety and satisfaction. Its targeted approach in servicing both the product and service aspects of the aesthetic treatment process reinforces Evolus’ reputation for precision, clarity, and performance in a fast-evolving industry.

Key Business Segments and Strategic Focus

Evolus focuses on:

  • Innovative Product Development: Utilizing advanced technology to deliver breakthrough aesthetic treatments.
  • Market Penetration: Effectively engaging physicians and medical aesthetic practitioners in the self-pay segment.
  • Distribution and Partnerships: Enhancing reach through strategic relationships in key international markets.
  • Customer-Centric Operations: Prioritizing patient outcomes with a structured approach to product application and safety.

The company’s integrated approach across these segments shows a commitment to operational excellence and continuous improvement.

Conclusion

In summary, Evolus Inc is a performance beauty company that has successfully positioned itself at the intersection of innovation and customer-focused medical aesthetics. With its proprietary formulation and comprehensive operational strategy, the company not only addresses the immediate cosmetic concerns of its customers but also reinforces its status as an informed and quality-driven participant in the competitive self-pay aesthetic market.

Stock Performance

$11.31
-2.08%
0.24
Last updated: April 25, 2025 at 10:44
0.43 %
Performance 1 year
$642.9M
Market Cap
63.6M
Shares outstanding

SEC Filings

No SEC filings available for Evolus.

Financial Highlights

$266,274,000
Revenue (TTM)
-$50,420,000
Net Income (TTM)
-$0.81
Diluted EPS (TTM)
-$17,999,000
Operating Cash Flow
-18.94%
Net Profit Margin
-12.92%
Oper. Profit Margin

Upcoming Events

May 7, 2025
Q1 2025 earnings call
April 7, 2026
25% RSU vesting
April 7, 2027
25% RSU vesting
April 7, 2028
25% RSU vesting
April 7, 2029
25% RSU vesting
March 7, 2026
RSU vesting date
March 7, 2027
RSU vesting date
March 7, 2028
RSU vesting date

Frequently Asked Questions

What is the current stock price of Evolus (EOLS)?

The current stock price of Evolus (EOLS) is $11.55 as of April 24, 2025.

What is the market cap of Evolus (EOLS)?

The market cap of Evolus (EOLS) is approximately 642.9M.

What is the revenue (TTM) of Evolus (EOLS) stock?

The trailing twelve months (TTM) revenue of Evolus (EOLS) is $266,274,000.

What is the net income of Evolus (EOLS)?

The trailing twelve months (TTM) net income of Evolus (EOLS) is -$50,420,000.

What is the earnings per share (EPS) of Evolus (EOLS)?

The diluted earnings per share (EPS) of Evolus (EOLS) is -$0.81 on a trailing twelve months (TTM) basis.

What is the operating cash flow of Evolus (EOLS)?

The operating cash flow of Evolus (EOLS) is -$17,999,000.

What is the profit margin of Evolus (EOLS)?

The net profit margin of Evolus (EOLS) is -18.94%.

What is the operating margin of Evolus (EOLS)?

The operating profit margin of Evolus (EOLS) is -12.92%.

What is the gross margin of Evolus (EOLS)?

The gross profit margin of Evolus (EOLS) is 68.46%.

What is the current ratio of Evolus (EOLS)?

The current ratio of Evolus (EOLS) is 2.40, indicating the company's ability to pay short-term obligations.

What is the gross profit of Evolus (EOLS)?

The gross profit of Evolus (EOLS) is $182,304,000 on a trailing twelve months (TTM) basis.

What is the operating income of Evolus (EOLS)?

The operating income of Evolus (EOLS) is -$34,411,000.

What is the primary focus of Evolus Inc?

Evolus Inc is focused on developing and marketing innovative medical aesthetic products, primarily in the self-pay cosmetic treatment market.

What is Jeuveau and why is it significant for Evolus?

Jeuveau is Evolus' proprietary purified botulinum toxin type A formulation designed to temporarily improve glabellar lines. It stands as the company’s flagship product and a key element of its innovative product portfolio.

How does Evolus generate revenue?

The company generates revenue through direct sales of Jeuveau in major markets and via service revenues from distribution partnerships, ensuring a diversified approach within the aesthetic sector.

What market does Evolus primarily serve?

Evolus primarily serves the self-pay aesthetic market, targeting physicians and their patients who seek effective, cosmetic improvement treatments.

How does Evolus differentiate itself from competitors?

Evolus differentiates itself through its advanced proprietary formulation, rigorous clinical practices, and a strong focus on customer outcomes within the competitive market of non-invasive aesthetic treatments.

What are the key business segments of Evolus Inc?

The company focuses on innovative product development, market penetration through physician engagement, strategic distribution partnerships, and maintaining high standards in customer-centric operations.

How does Evolus address safety and effectiveness in its products?

Evolus uses advanced technology and clinical research to ensure that its products meet rigorous safety and efficacy standards, providing reliable results in aesthetic enhancements.

Can you compare Evolus with other companies in the aesthetic medicine industry?

While many companies operate in the aesthetic medicine field, Evolus is distinct for its specific focus on the self-pay market and for leveraging advanced formulations that cater to precise cosmetic concerns.